StageZero Life Sciences Ltd. (OTCMKTS:GNWSD – Get Free Report) was up 31% on Wednesday . The stock traded as high as $0.12 and last traded at $0.12. Approximately 28,487 shares changed hands during trading, an increase of 471% from the average daily volume of 4,987 shares. The stock had previously closed at $0.09.
StageZero Life Sciences Price Performance
The business has a 50 day simple moving average of $0.06 and a 200 day simple moving average of $0.04.
About StageZero Life Sciences
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.
Recommended Stories
- Five stocks we like better than StageZero Life Sciences
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Top Biotech Stocks: Exploring Innovation Opportunities
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- How to Buy Cheap Stocks Step by Step
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
